Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome submitted a New Drug Application to the FDA for varegacestat for the treatment of adults with desmoid tumors. The submission is supported by Phase 3 RINGSIDE data showing an 84% reduction in the risk of disease progression or death and an objective response rate of 56%.
Key figures
- Drug Name
- Varegacestat
- Phase Of Trial
- Phase 3
- P value
- <0.0001
- Hazard ratio
- 0.16
- Patients randomized
- 156
- Median tumor volume reduction
- -83%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.